STOCK TITAN
  1. Home
  2. Sec-filings
  3. TVTX
  4. [Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Travere (TVTX) insider donates 1,078 shares under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/31/2025, the officer sold 5,591 shares of common stock at $35 per share under a Rule 10b5-1 trading plan adopted on June 16, 2025. On 11/03/2025, the officer made a charitable gift of 1,078 shares to a donor advised fund, also pursuant to the same 10b5-1 plan.

Following these transactions, the officer beneficially owned 117,993 shares, held directly.

Positive

  • None.

Negative

  • None.
Insider Heerma Peter
Role CHIEF COMMERCIAL OFFICER
Sold 5,591 shs ($196K)
Type Security Shares Price Value
Gift Common Stock 1,078 $0.00 --
Sale Common Stock 5,591 $35.00 $196K
Holdings After Transaction: Common Stock — 117,993 shares (Direct)
Footnotes (1)
  1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. This transaction represents a charitable gift of 1,078 shares of common stock to a donor advised fund, which was gifted pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Heerma Peter
(Last) (First) (Middle)
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF COMMERCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/31/2025 S(1) 5,591 D $35 119,071 D
Common Stock 11/03/2025 G(2) 1,078 D $0 117,993 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. This transaction represents a charitable gift of 1,078 shares of common stock to a donor advised fund, which was gifted pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
/s/ Elizabeth E. Reed, Attorney-in-Fact 11/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did TVTX disclose?

The Chief Commercial Officer sold 5,591 shares at $35 on 10/31/2025 and made a charitable gift of 1,078 shares on 11/03/2025.

How many TVTX shares does the insider own after the transactions?

The officer beneficially owned 117,993 shares directly after the reported transactions.

Were the TVTX transactions under a 10b5-1 plan?

Yes. Both transactions were executed pursuant to a Rule 10b5-1(c) plan adopted on June 16, 2025.

What roles does the reporting person hold at TVTX?

The reporting person is an officer, serving as Chief Commercial Officer.

What was the price of the TVTX share sale?

The sale price reported was $35 per share.

What was the nature of the second TVTX transaction?

It was a charitable gift of 1,078 shares to a donor advised fund.